Why TNBC Demands a New Generation of Targeted Therapy

Triple-negative breast cancer is defined by the simultaneous absence of oestrogen receptor (ER), progesterone receptor (PR), and HER2 expression — the very molecular handles that have driven decades of targeted oncology progress in other breast cancer subtypes. Without these receptors, patients have historically been confined to cytotoxic chemotherapy regimens, which carry substantial toxicity burdens and produce responses that are frequently incomplete and short-lived.

The emergence of antibody-drug conjugates (ADCs) as a therapeutic modality has opened a new chapter for TNBC. ADCs combine the tumour-targeting precision of monoclonal antibodies with the cytotoxic potency of small-molecule payloads, delivering chemotherapy directly to cancer cells while sparing, at least in principle, healthy tissue. TROP2 — trophoblast cell-surface antigen 2 — has become one of the most compelling targets in this space, owing to its high and relatively uniform overexpression across TNBC tumours and its efficient internalisation upon antibody binding, as noted in published oncology literature reviewed by Nature.

Two TROP2-directed ADCs have advanced furthest in clinical development for TNBC: datopotamab deruxtecan (Dato-DXd, also designated DS-1062), co-developed by AstraZeneca and Daiichi Sankyo, and sacituzumab govitecan (SG, brand name Trodelvy), originally developed by Immunomedics and now commercialised by Gilead Sciences following an acquisition. Their head-to-head differentiation — across mechanism, clinical signal, intellectual property, and combination potential — is increasingly central to oncology pipeline strategy and competitive intelligence.

TROP2 as a Therapeutic Target: Expression, Internalisation, and Selectivity

TROP2 (encoded by the TACSTD2 gene) is a transmembrane glycoprotein that is overexpressed in a broad range of epithelial malignancies, with particularly high and consistent expression levels documented in TNBC tumour tissue. Its utility as an ADC target depends on three properties: high tumour expression relative to normal tissue, efficient receptor-mediated internalisation upon antibody engagement, and a degree of tumour selectivity that limits on-target, off-tumour toxicity.

TROP2 expression in TNBC is not binary. Tumour heterogeneity means that expression levels vary across patients and, to a lesser extent, within individual tumours. This heterogeneity has important implications for patient selection and biomarker strategy: ADCs that can exploit a bystander killing effect — where released payload diffuses to adjacent TROP2-low or TROP2-negative cells — may be less dependent on uniformly high target expression than those relying solely on receptor-mediated internalisation. The degree to which each ADC harnesses this bystander mechanism is partly a function of linker design and payload membrane permeability, as discussed in ADC pharmacology literature published by The New England Journal of Medicine.

From a selectivity standpoint, TROP2 is expressed at lower levels in several normal tissues, including the kidney, lung, and gastrointestinal epithelium. This background expression is clinically relevant: it partly explains the class-specific toxicities seen with TROP2-directed ADCs, including stomatitis and haematological adverse events. Understanding the quantitative relationship between TROP2 expression levels and ADC-mediated toxicity remains an active area of translational research, with regulatory agencies including the FDA placing increasing emphasis on companion diagnostic development for ADC programmes.

Mechanistic Differentiation: Linker, Payload, and DAR Compared

Dato-DXd and sacituzumab govitecan share a common target but diverge substantially in every other dimension of ADC engineering — antibody scaffold, linker chemistry, cytotoxic payload, and drug-to-antibody ratio (DAR). These differences are not merely academic: they translate directly into distinct pharmacokinetic profiles, tolerability patterns, and potential resistance mechanisms.

“Both Dato-DXd and sacituzumab govitecan carry topoisomerase I inhibitor payloads against the same TROP2 target — yet their linker chemistry, drug-to-antibody ratio, and payload potency create meaningfully different clinical and safety profiles in triple-negative breast cancer.”

The linker is perhaps the most consequential engineering variable. Dato-DXd employs a tetrapeptide (GGFG) cleavable linker that is selectively cleaved by lysosomal proteases following internalisation, limiting systemic payload release and potentially reducing off-target toxicity. Sacituzumab govitecan uses a hydrolysable CL2A linker that is susceptible to pH-sensitive hydrolysis in the bloodstream, resulting in a measurable fraction of free SN-38 in circulation. This partially explains the higher incidence of haematological toxicity — particularly neutropenia — observed with SG in clinical trials.

The payload potency gap is also significant. DXd is a highly potent exatecan derivative with approximately 10-fold greater in vitro cytotoxicity than SN-38, meaning Dato-DXd can potentially achieve therapeutic effect with a lower DAR (~4) compared with SG’s higher DAR (~7.6). A lower DAR generally confers better pharmacokinetic behaviour and reduced aggregation risk, but may narrow the therapeutic window in tumours with heterogeneous TROP2 expression where bystander effect is relied upon for coverage of antigen-low cells.

Clinical Development Signals and Regulatory Milestones

Sacituzumab govitecan holds a clear regulatory lead in TNBC: it received FDA accelerated approval for adult patients with unresectable locally advanced or metastatic TNBC who had received at least two prior therapies, subsequently converted to regular approval on the strength of the ASCENT trial. This positions SG as an established standard of care in later-line TNBC, with a defined label and commercially available product.

Datopotamab deruxtecan is in active Phase III development for TNBC through the TROPION-Breast programme. Earlier Phase I/II data from TROPION-PanTumor demonstrated activity in heavily pre-treated solid tumours including breast cancer, providing the clinical rationale for the registrational programme. The competitive dynamic between Dato-DXd and SG in TNBC is therefore partly a race between an approved agent with established commercial infrastructure and a late-stage investigational agent with a potentially differentiated mechanistic profile.

One important nuance in the clinical comparison is the patient population context. SG’s pivotal ASCENT trial enrolled patients who had received at least two prior lines of therapy, establishing its label in the later-line setting. The TROPION-Breast programme includes trials exploring earlier lines of therapy, which could position Dato-DXd in a complementary rather than directly competitive space — or, if positive, as a line-shift agent that displaces SG in earlier settings. Regulatory bodies including the European Medicines Agency will scrutinise cross-trial comparisons carefully given differences in patient populations, prior treatment history, and trial design.

Safety profile differentiation will also influence clinical adoption. SG’s known toxicities include neutropenia, diarrhoea, nausea, and alopecia — a profile reflecting both its higher DAR and the moderate linker stability. Early Dato-DXd data suggest a somewhat different toxicity signature, with stomatitis emerging as a notable adverse event, potentially reflecting the distribution of TROP2 expression in oral mucosal tissue. Head-to-head tolerability comparisons in the same patient population remain unavailable, making indirect inference from separate trial datasets the current standard of evidence.

Combination Strategies, IP Landscape, and Resistance Considerations

Combination strategies represent a critical frontier for both TROP2-directed ADCs in TNBC, given the near-universal expectation that monotherapy responses will be limited by acquired resistance. The mechanistic rationale for combination varies by partner agent and is shaped by the distinct biology of each ADC.

Combination Partner Rationale

Immune checkpoint inhibitors (anti-PD-1 and anti-PD-L1 antibodies) are a natural combination partner for both agents, given the immunogenic cell death that topoisomerase I inhibitor payloads can induce. Payload-mediated DNA damage may upregulate tumour immunogenicity, potentially synergising with checkpoint blockade. Clinical trials exploring SG plus checkpoint inhibitors in TNBC are underway, and similar investigations are planned or active for Dato-DXd. The feasibility of these combinations is partly constrained by overlapping toxicity — particularly the haematological burden of SG combined with immune-related adverse events.

For BRCA-mutated TNBC — a genetically defined subpopulation — PARP inhibitors represent a scientifically grounded combination partner. PARP inhibitors exploit homologous recombination deficiency, and topoisomerase I inhibitor payloads generate replication fork stalling that may be synthetically lethal in the same genomic context. This mechanistic convergence has generated investigator interest in ADC-plus-PARP inhibitor combinations, though clinical validation remains at early stages for both Dato-DXd and SG in this combination context.

Resistance Mechanisms

Resistance to TROP2-directed ADCs is an emerging area of translational investigation. Proposed mechanisms include TROP2 downregulation or mutation (reducing target availability), alterations in lysosomal trafficking (impairing intracellular payload release), upregulation of drug efflux transporters (reducing intracellular payload accumulation), and acquired mutations in topoisomerase I (reducing payload target engagement). The relative importance of each mechanism may differ between Dato-DXd and SG given their distinct linker-payload architectures, and cross-resistance between the two agents is not yet well characterised clinically.

Intellectual Property Landscape

The IP landscape surrounding TROP2-directed ADCs is substantial and actively contested. Patent families covering TROP2-targeting antibodies, linker-payload conjugation chemistries, and manufacturing processes have been filed by AstraZeneca, Daiichi Sankyo, Gilead Sciences, and their predecessors across major jurisdictions including the United States, Europe, Japan, and China. According to global patent monitoring standards published by WIPO, ADC-related patent filings have grown substantially over the past decade, reflecting the competitive intensity of the field. Freedom-to-operate analysis and patent expiry timelines are therefore critical inputs for any competitive intelligence assessment of this space.